Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 3 5Phase EARLY_PHASE1 4Phase 2 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 699Breast Neoplasms 629Neoplasms 582Leukemia, Myeloid, Acute 481Colorectal Neoplasms 455Multiple Myeloma 444Melanoma 424Prostatic Neoplasms 383Neoplasm Metastasis 370Pancreatic Neoplasms 361Recurrence 347Lymphoma 340Ovarian Neoplasms 322Lung Neoplasms 297Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 219Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Triple Negative Breast Neoplasms 167Lymphoma, Mantle-Cell 167

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Neuromyelitis Optica × Clear all
NCT07022197 2025-06-15

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Tianjin Medical University General Hospital

Phase 1/2 Recruiting
27 enrolled

Myasthenia Gravis, Myositis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡